Leukemia is a blood cancer that occurs when white blood cells in the bone marrow grow out of control. While it is the most common form of childhood cancer, leukemia is also the most curable form of cancer in children.
The experienced team of multidisciplinary specialists at the University of Michigan C.S. Mott Children’s Hospital Pediatric Oncology Program has the diagnostic capabilities and cutting-edge therapies, including novel clinical trials, to provide world-class care for children with leukemia. In addition, our Blood and Marrow Transplantation Program is one of the largest and most innovative in the country.
Leukemia symptoms and diagnosis
Common leukemia symptoms include weakness, bone pain, fever, easy bleeding and bruising. Leukemia is diagnosed with a blood test. Other tests, such as flow cytometry, which examines cells and chromosomes under a microscope, are used to identify the type of leukemia, and chromosome studies determine how to best treat the leukemia. We also use newer diagnostic techniques, including minimal residual disease measurement, to help our pediatric oncologists determine how well treatment is working and how to modify the therapy when needed.
We treat all forms of childhood leukemia, including:
- Acute lymphoblastic leukemia (ALL)
- Acute myelogenous leukemia (AML)
- Other uncommon leukemia types, such as juvenile myelomonocytic leukemia and chronic myeloid leukemia
Treatments vary depending on type of leukemia as well as other variables, but can include chemotherapy, targeted biological therapy (using the patient’s immune system to help fight cancer and minimize side effects) and bone marrow transplant. Pediatric oncologists, surgeons, radiation oncologists, pathologists, radiologists and nuclear medicine physicians make up our expert treatment team.
Leukemia clinical trials
We also have several clinical trials available for novel therapies, offered in conjunction with the Children’s Oncology Group, our own Blood and Marrow Transplant Consortium, and Therapeutic Advances in Childhood Leukemia (TACL). In fact, we are one of only 16 centers in the country that are part of TACL, a consortium focusing on developing new and innovative trials for relapsed or resistant leukemia.
Through our Stem Cell Initiatives, our researchers are developing a better understanding of leukemia stem cells to create better clinical trials and revolutionize how we treat cancer.
Schedule an appointment by calling us at 734-936-9814.